Randomized Controlled Trial of Mobile Closed-Loop Control
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS: This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c <10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS: Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P < 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P < 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS: In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One of these studies became the International Diabetes Closed-Loop (iDCL) Trial, which tested two algorithms originally designed in silico. 130,131”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [130]
In the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“being translated into clinical practice: following a pivotal trial and regulatory approval in 2017, the Medtronic MiniMed 670G is now commercially available and used clinically (4).”
MethodSelf-citationLachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group (2008) · Diabetes · doi:10.2337/db07-1618 · Cited by 555
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463 · cited 2×
“study are consistentwith theexpectations for a closed-loopsystem: improved time in a target range and reduced risk/exposure tohypo-andhyperglycemia (18,19).”
BackgroundTauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Self-citationGlycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Cryer, P. E. (2014) · Diabetes · doi:10.2337/db14-0059 · Cited by 236
Benhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Cited by
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Self-citation7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Self-citationOne Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Self-citation7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
McAuley, S. A., Lee, M. H., Paldus, B., Vogrin, S., de Bock, M. I., Abraham, M. B., Bach, L. A., Burt, M. G., Cohen, N. D., Colman, P. G., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1447 · Cited by 158
Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy
Fuchs, J., & Hovorka, R. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1784724 · Cited by 82
“In the three month parallel group study there were no DKA events and one severe hypoglycaemia event not related to device malfunction (48).”
BackgroundMethodBisio, A., Gonder-Frederick, L., McFadden, R., Cherñavvsky, D., Voelmle, M., Pajewski, M., Yu, P., Bonner, H., & Brown, S. A. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820986879 · Cited by 76
Self-citationJiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01144-4 · Cited by 67
“…(Tandem) [33, 35, 36, 38, 45]; two (n = 144) assessed Modified Florence [30, 31]; two (n = 119) assessed MiniMed 780G (Medtronic) [8, 29]; two assessed openAPS (n = 129) [34, 41]; one (n = 63) assessed DBLG1 (Dbl-diabetes) [40]; and one (n = 219) assessed iLet Bionic Pancreas (Beta Bionics) [12].”
Time in range centered diabetes care
Dovč, K., & Battelino, T. (2021) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.30.1 · Cited by 70
Fabris, C., Heinemann, L., Beck, R., Cobelli, C., & Kovatchev, B. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0236 · Cited by 58
Self-citationBisio, A., Brown, S. A., McFadden, R., Pajewski, M., Yu, P. L., DeBoer, M., Schoelwer, M. J., Bonner, H. G., Wakeman, C. A., Cherñavvsky, D. R., et al. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13164 · Cited by 57
Self-citationGarcia‐Tirado, J., Lv, D., Corbett, J. P., Colmegna, P. H., & Breton, M. D. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106401 · Cited by 48
Self-citationDeveloping the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Self-citationMontaser, E., Fabris, C., & Kovatchev, B. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0104 · Cited by 41
Self-citationMontaser, E., Farhy, L. S., & Kovatchev, B. P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae379 · Cited by 50
Self-citationA Data-Driven Approach to Classifying Daily Continuous Glucose Monitoring (CGM) Time Series
Lobo, B. J., Farhy, L. S., Shafiei, M., & Kovatchev, B. P. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2021.3103127 · Cited by 40
Self-citationAutomated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes
Garcia‐Tirado, J., Farhy, L. S., Nass, R. M., Kollar, L. L., Oliveri, M. C., Basu, R., Kovatchev, B. P., & Basu, A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0542 · Cited by 39
Self-citationStahl‐Pehe, A., Mashhadi, N. S., Wirth, M., Schlesinger, S., Kuß, O., Holl, R. W., Bächle, C., Warz, K.-D., Bürger-Büsing, J., Spörkel, O., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103190 · Cited by 42
Jacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A. X., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00358-x · Cited by 40
“In studies where HbA1c was the primary outcome, whether assessing the use of the Medtronic 780 G in adults who were previously managed with MDI and isCGM 79 or in 6 – 18-year-olds using the CamAPS FX AID system,(84) AID systems were found to be superior to the comparator groups.”
MethodSelf-citationHaidar, A., Legault, L., Raffray, M., Gouchie‐Provencher, N., Jacobs, P. G., Fathi, A. E., Rutkowski, J., Messier, V., & RABASA-LHORET, R. P. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0365 · Cited by 34
Kang, S. L., Hwang, Y. N., Kwon, J. Y., & Kim, S. M. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00962-2 · Cited by 32
“[43] 2020 125 Accu-Chek Spirit Combo insulin pump, Dexcom CGM”
MethodCoutant, R., Bismuth, É., Bonnemaison, É., Dalla‐Vale, F., Morinais, P., Perrard, M., Trely, J., Faure, N., Bouhours‐Nouet, N., Levaillant, L., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0518 · Cited by 26
Self-citationThe closed‐loop artificial pancreas in 2020
Fabris, C., & Kovatchev, B. P. (2020) · Artificial Organs · doi:10.1111/aor.13704 · Cited by 24
Self-citationDiaz C., J. L., Fabris, C., Breton, M. D., & Cengiz, E. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0154 · Cited by 19
Self-citationEvidence from clinical trials on high-risk medical devices in children: a scoping review
Guerlich, K., Patro-Gołąb, B., Dworakowski, P., Fraser, A. G., Kammermeier, M., Melvin, T., & Koletzko, B. V. (2023) · Pediatric Research · doi:10.1038/s41390-023-02819-4 · Cited by 17
Identifiability of Control-Oriented Glucose-Insulin Linear Models: Review and Analysis
Hoyos, J. D., Villa-Tamayo, M. F., Builes-Montaño, C. E., Rincón, A. R., Godoy, J. L., Garcia‐Tirado, J., & Rivadeneira, P. S. (2021) · IEEE Access · doi:10.1109/access.2021.3076405 · Cited by 17
Fox, D. S., Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Tauschmann, M., Denvir, L., Thankamony, A., Campbell, F., Wadwa, R. P., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241231950 · Cited by 18
Self-citationGlycaemic variabilities: Key questions in pursuit of clarity
Monnier, L., Owens, D. R., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101283 · Cited by 16
Kesavadev, J., Basanth, A., Krishnan, G., Shankar, A., Sanal, G., & Jothydev, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01427-z · Cited by 16
Mise en place de l’insulinothérapie automatisée en boucle fermée : position d’experts français
Franc, S., Schaepelynck, P., Tubiana‐Rufi, N., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(20)30003-1 · Cited by 24
Alfadli, S. F., Alotaibi, Y. S., Aqdi, M. J., Almozan, L. A., Alzubaidi, Z. B., Altemani, H. A., Almutairi, S. D., Alabdullah, H. A., Almehmadi, A. A., Alanzi, A. L., et al. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100382 · Cited by 16
Artificial Pancreas Technology Offers Hope for Childhood Diabetes
Schoelwer, M. J., & DeBoer, M. D. (2021) · Current Nutrition Reports · doi:10.1007/s13668-020-00347-9 · Cited by 11
“Mean age 45.5 years Kovatchev et al. (2020) [55] Tandem Control-IQ Randomized crossover N = 80 8 months Use of HCL only in the evenings and overnight reduced hypoglycemia compared to SAP and achieved most of the glycemic benefits of 24-7 HCL Age 18–69 years Forlenza et al. (2019) [21••] Medtronic…”
MethodInfluentialZuniga-Kennedy, M., Wang, O. H., Fonseca, L. M., Cleveland, M. J., Bulger, J., Grinspoon, E. A., Hansen, D., Hawks, Z., Jung, L., Singh, S. M., et al. (2024) · The Clinical Neuropsychologist · doi:10.1080/13854046.2024.2315749 · Cited by 10
“…commercially available automated insulin delivery via a hybrid closed-loop system has been shown to reduce the amount of time individuals spend in hypoglycemia at night by approximately 2% (Kovatchev et al., 2020), which would be equivalent to a 208 ms improvement in next day processing speed.”
Decision Support Systems and Closed‐Loop
Nimri, R., Phillip, M., & Kovatchev, B. P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.2504 · Cited by 9
Self-citationAlwan, H., Ware, J., Boughton, C. K., Wilinska, M. E., Allen, J. M., Lakshman, R., Nwokolo, M., Hartnell, S., Bally, L., de Beaufort, C. E., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0061 · Cited by 7
Jabari, M. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-40423-y · Cited by 11
“Six studies 37–41,43”
Monnier, L., Colette, C., Renard, É., Benhamou, P., Aouinti, S., Molinari, N., & Owens, D. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101589 · Cited by 8
Suboptimally Controlled Diabetes in Pregnancy: A Review to Guide Antepartum and Delivery Management
Cate, J. J. M., Bloom, E. A., Chu, A., Bauer, S., Kuller, J. A., & Dotters-Katz, S. K. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001270 · Cited by 7
“47 – 51 In one multicenter RCT published in the New England Journal of Medicine , hybrid closed-loop systems were found to improve glycemic control by increasing the TIR and reducing hyperglycemic episodes in pregnant individuals with type 1 diabetes suggestive of a role for this technology in…”
BackgroundOverview of Currently Available Insulin Delivery Systems
Fried, H. (2024) · Contemporary Endocrinology · doi:10.1007/978-3-031-75352-7_2 · Cited by 4
Hybrid Closed-Loop Insulin Delivery Systems for People With Type 1 Diabetes
Service, C. H. T. A. (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.50 · Cited by 4
Glycemic variability and iatrogenic hypoglycemia: how to resolve
Monnier, L., Colette, C., Renard, É., Benhamou, P., Aouinti, S., Molinari, N., & Owens, D. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112360 · Cited by 3
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Monnier, L., Colette, C., Bonnet, F., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.11.003 · Cited by 3
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18802.hz · Cited by 3
Self-citationMonnier, L., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.12.006 · Cited by 2
Sidki, A., HIGHTON, P. J., O’Mahoney, L. L., & Wilkinson, T. J. (2026) · Diabetic Medicine · doi:10.1111/dme.70210 · Cited by 1
Perioperative Medication Management for Patients with Diabetes
Duggan, E. W., & Mazer, C. D. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.11.010 · Cited by 1
Wang, H., He, L., Wang, X., Du, Y., Mu, Z., Shi, Y., Wang, Y., Qiao, Q., Tong, Q., & Zheng, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1701350 · Cited by 1
“Studies indicate that these tools lead to signi fi cantly better outcomes in terms of weight loss and blood glucose improvement than conventional care does (37).”
Liu, Y., Wang, Y., Wu, W., Chen, Y., Zeng, T., Li, X., Zheng, C., Li, Y., Wu, X., Yao, H., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70709 · Cited by 1
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251335685 · Cited by 2
Self-citationJacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · medRxiv · doi:10.1101/2023.04.15.23288624
“metabolic endpoints such as increased glycemic variability and increased BMI in an SAP vs MDI trial,(55) no change in hypoglycemia measures in an AID trial where adults demonstrated improvement,(91) and males (age 14 years and up) failed to improve TAR while females did.(83) A”
BackgroundSelf-citationJiao, X., & Shen, Y. (2023) · Journal of Diabetes and Clinical Research · doi:10.33696/diabetes.4.055
“The analysis included ten articles [1-10], covering 11 studies with 817 participants.”
BackgroundIklé, J. M., Addala, A., & Maahs, D. M. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch69
Traiter les hypoglycémies iatrogènes à l’ère des nouvelles technologies
Monnier, L., & Colette, C. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.02.002
Artificial Intelligence (AI) in Medicine and Endocrinology
Sharghi, S., & Larijani, B. A. (2025) · Springer eBooks · doi:10.1007/978-981-95-2286-6_3 · Cited by 1
Kang, S. L., Hwang, Y. N., Kwon, J. Y., & Kim, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26552224
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26620396
Metadata
- Authors
- Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., Brown, S. A., Church, M. M., Dadlani, V., Dassau, E., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Lum, J., Beck, R. W., iDCL Study Group, Kovatchev, B., Anderson, S. M., Brown, S. A., Emory, E., Voelmle, M., Conshafter, K., Morris, K., Oliveri, M., Mitchell, H., Calvo, K., Wakeman, C., Breton, M., Laffel, L. M., Isganaitis, E., Ambler-Osborn, L., Flint, E., Schultz, A., Kim, K., Pinsker, J. E., Church, M. M., Andre, C., Levy, C., Lam, D. W., O’Malley, G., Levister, C., Ogyaadu, S., Kudva, Y. C., Dadlani, V., Simha, V., McCrady-Spitzer, S., Reid, C., Wadwa, R. P., Forlenza, G. P., Jost, E., Messer, L., Berget, C., Towers, L., Buckingham, B., Ekhlaspour, L., Hsu, L., Loebner, S., Doyle, F. J., Dassau, E., Lum, J., Beck, R. W., Campos, T., Passman, S., Murphy, C., Patibandla, N., Raghinaru, D., & Kollman, C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-14
- Volume
- 43
- Issue
- 3
- Pages
- 607-615
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7035585
- OpenAlex
- W3000000785
- Semantic Scholar
- 1fb5a32cad7ab49b4e9b868744caaab314a5e229
- Cited by
- 60
- References
- 23
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 12 · 2020: 8
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-06-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4-DK-108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, sensor-augmented pump, continuous glucose monitoring, insulin pump therapy, hypoglycemia, hyperglycemia, glycemic control, non-inferiority
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, United States, Blood Glucose Self-Monitoring, Biosensing Techniques, Telemedicine, Pancreas, Artificial, Young Adult, Insulin, Regular, Human, Mobile Applications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.